A Phase 3 interventional study of Adalimumab in Juvenile Rheumatoid Arthritis, sponsored by Abbott. Completed at 12 sites in Japan. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2012-09-10.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Juvenile with a site in Japan — 3 open to participants now, 6 under way, 5 of them phase 3. Arthritis, Juvenile · Japan.
Among the 12 studies in Arthritis, Juvenile with a site in Japan, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2008, is one of 10 in phase 3, and was the 1st registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →3 of the 12 studies in Arthritis, Juvenile with a site in Japan are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Japan, United States, Argentina and 15 more countries
Ages 3+
AbbVie · Sites in Japan, United States, Argentina and 14 more countries
Ages 1–17
Eli Lilly and Company · Sites in Japan, Argentina, Australia and 17 more countries
Ages 1–18
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 58 across the 11 interventional studies, 113 across the 1 observational. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 8 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 2 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Arthritis, Juvenile with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese children with Polyarticular Juvenile Rheumatoid Arthritis
This was an open-label long-term study that was completed following study drug approval in Japan for the treatment of JRA. Data are presented through Week 144 and for the final visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Adalimumab
Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
Also known as: adalimumab, ABT-D2E7, Humira
Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16
Response defined as at least 30% improvement in 3 or more of 6 juvenile rheumatoid arthritis (JRA) core set criteria, and at least 30% worsening in not more than 1 JRA criterion, compared with baseline. JRA core set criteria include physician's global assessment of disease severity; parent's/patient's global assessment of overall well-being; number of active joints (joints with swelling or with limitation of motion \[LOM\] and with pain, tenderness or both); number of joints with LOM; physical function of the Disability Index of Childhood Health Assessment Questionnaire; C-reactive protein.
Time frame: Week 16
Number of Subjects Achieving PedACR50 and PedACR70 Responses at Week 16
Response defined as at least 50/70% improvement in 3 or more of 6 juvenile rheumatoid arthritis (JRA) core set criteria, and at least 50/70% worsening in not more than 1 JRA criterion compared with baseline. JRA core set criteria include physician's global assessment of disease severity; parent's/patient's global assessment of overall well-being; number of active joints (joints with swelling or with limitation of motion \[LOM\] and with pain, tenderness or both); number of joints with LOM; physical function of the Disability Index of Childhood Health Assessment Questionnaire; C-reactive protein.
Time frame: Week 16
Number of Subjects Achieving PedACR 30/50/70 Responses
Time frame: Week 2, 4, 8, and 24, every 12 weeks from Week 24 to Week 60, and every 24 weeks from Week 72 to the final visit
Mean Serum Adalimumab Concentration
Blood samples were drawn prior to drug administration. Adalimumab concentrations in serum were determined using a validated enzyme-linked immunosorbent assay (ELISA) method based on a double-antigen technique. Concentrations are reported as micrograms per milliliter (mcg/mL).
Time frame: Week 2, 4, 8, 16, and 24, and every 12 weeks up to Week 60
Number of Subjects Positive for Anti-adalimumab Antibodies (AAA)
Serum samples with adalimumab concentration below 2 mcg/mL were selected for AAA analyses. Samples were considered AAA positive if the measured AAA concentration was above 20 ng/mL. A subject was considered to be AAA positive if the subject had at least one AAA positive sample observed within 30 days following the subject's last adalimumab dose.
Time frame: Week 24 and Week 60
| Milestone | Adalimumab |
|---|---|
| Started | 25 |
| Completed | 16 |
| Not completed | 9 |
| Withdrew: Lack of efficacy | 8 |
| Withdrew: Withdrawal by subject | 1 |
Response defined as at least 30% improvement in 3 or more of 6 juvenile rheumatoid arthritis (JRA) core set criteria, and at least 30% worsening in not more than 1 JRA criterion, compared with baseline. JRA core set criteria include physician's global assessment of disease severity; parent's/patient's global assessment of overall well-being; number of active joints (joints with swelling or with limitation of motion \[LOM\] and with pain, tenderness or both); number of joints with LOM; physical function of the Disability Index of Childhood Health Assessment Questionnaire; C-reactive protein.
| Participants | Adalimumab |
|---|---|
| Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16 | 23 |
Response defined as at least 50/70% improvement in 3 or more of 6 juvenile rheumatoid arthritis (JRA) core set criteria, and at least 50/70% worsening in not more than 1 JRA criterion compared with baseline. JRA core set criteria include physician's global assessment of disease severity; parent's/patient's global assessment of overall well-being; number of active joints (joints with swelling or with limitation of motion \[LOM\] and with pain, tenderness or both); number of joints with LOM; physical function of the Disability Index of Childhood Health Assessment Questionnaire; C-reactive protein.
| Participants | Adalimumab |
|---|---|
| Number of Subjects Achieving PedACR50 at Week 16 | 22 |
| Number of Subjects Achieving PedACR70 at Week 16 | 15 |
| Participants | Adalimumab |
|---|---|
| Number of subjects achieving PedACR30 at Week 2 | 15 |
| Number of subjects achieving PedACR30 at Week 4 | 16 |
| Number of subjects achieving PedACR30 at Week 8 | 19 |
| Number of subjects achieving PedACR30 at Week 24 | 21 |
| Number of subjects achieving PedACR30 at Week 36 | 22 |
| Number of subjects achieving PedACR30 at Week 48 | 21 |
| Number of subjects achieving PedACR30 at Week 60 | 20 |
| Number of subjects achieving PedACR30 at Week 72 | 19 |
| Number of subjects achieving PedACR30 at Week 96 | 18 |
| Number of subjects achieving PedACR30 at Week 120 | 11 |
| Number of subjects achieving PedACR30 at Week 144 | 5 |
| Number of subjects achieving PedACR30- Final Visit | 22 |
| Number of subjects achieving PedACR50 at Week 2 | 7 |
| Number of subjects achieving PedACR50 at Week 4 | 13 |
| Number of subjects achieving PedACR50 at Week 8 | 15 |
| Number of subjects achieving PedACR50 at Week 24 | 19 |
| Number of subjects achieving PedACR50 at Week 36 | 22 |
| Number of subjects achieving PedACR50 at Week 48 | 19 |
| Number of subjects achieving PedACR50 at Week 60 | 20 |
| Number of subjects achieving PedACR50 at Week 72 | 18 |
| Number of subjects achieving PedACR50 at Week 96 | 18 |
| Number of subjects achieving PedACR50 at Week 120 | 11 |
| Number of subjects achieving PedACR50 at Week 144 | 5 |
| Number of subjects achieving PedACR50- Final Visit | 20 |
| Number of subjects achieving PedACR70 at Week 2 | 1 |
| Number of subjects achieving PedACR70 at Week 4 | 7 |
| Number of subjects achieving PedACR70 at Week 8 | 8 |
| Number of subjects achieving PedACR70 at Week 24 | 15 |
| Number of subjects achieving PedACR70 at Week 36 | 19 |
| Number of subjects achieving PedACR70 at Week 48 | 17 |
| Number of subjects achieving PedACR70 at Week 60 | 16 |
| Number of subjects achieving PedACR70 at Week 72 | 15 |
| Number of subjects achieving PedACR70 at Week 96 | 14 |
| Number of subjects achieving PedACR70 at Week 120 | 11 |
| Number of subjects achieving PedACR70 at Week 144 | 5 |
| Number of subjects achieving PedACR70- Final Visit | 17 |
Blood samples were drawn prior to drug administration. Adalimumab concentrations in serum were determined using a validated enzyme-linked immunosorbent assay (ELISA) method based on a double-antigen technique. Concentrations are reported as micrograms per milliliter (mcg/mL).
| mcg/mL | Adalimumab |
|---|---|
| 20 mg dose at Week 2 | 5.24 ± 1.74 |
| 20 mg dose at Week 4 | 5.46 ± 5.18 |
| 20 mg dose at Week 8 | 6.15 ± 5.88 |
| 20 mg dose at Week 16 | 5.73 ± 5.26 |
| 20 mg dose at Week 24 | 5.79 ± 6.51 |
| 20 mg dose at Week 36 | 7.60 ± 7.58 |
| 20 mg dose at Week 48 | 7.97 ± 6.69 |
| 20 mg dose at Week 60 | 11.4 ± 9.87 |
| 40 mg dose at Week 2 | 5.03 ± 1.45 |
| 40 mg dose at Week 4 | 5.63 ± 2.71 |
| 40 mg dose at Week 8 | 8.66 ± 4.41 |
| 40 mg dose at Week 16 | 10.8 ± 6.15 |
| 40 mg dose at Week 24 | 11.9 ± 6.80 |
| 40 mg dose at Week 36 | 12.6 ± 6.44 |
| 40 mg dose at Week 48 | 13.0 ± 8.89 |
| 40 mg dose at Week 60 | 13.1 ± 6.73 |
Serum samples with adalimumab concentration below 2 mcg/mL were selected for AAA analyses. Samples were considered AAA positive if the measured AAA concentration was above 20 ng/mL. A subject was considered to be AAA positive if the subject had at least one AAA positive sample observed within 30 days following the subject's last adalimumab dose.
| Participants | Adalimumab |
|---|---|
| Number of subjects with AAA by Week 24 | 4 |
| Number of subjects with AAA by Week 60 | 6 |
Collected over All adverse events reported from the time of first study drug administration until 70 days following discontinuation of study drug administration were collected.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab | — | 6/25 (24%) | 25/25 (100%) |
| Event | Adalimumab |
|---|---|
| pyrexiaGeneral disorders | 2/25 |
| hepatitis BInfections and infestations | 1/25 |
| herpes zosterInfections and infestations | 1/25 |
| pharyngitisInfections and infestations | 1/25 |
| pneumoniaInfections and infestations | 1/25 |
| dehydrationMetabolism and nutrition disorders | 1/25 |
| arthralgiaMusculoskeletal and connective tissue disorders | 1/25 |
| juvenile arthritisMusculoskeletal and connective tissue disorders | 1/25 |
| amnesiaNervous system disorders | 1/25 |
| pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 1/25 |
| Event | Adalimumab |
|---|---|
| nasopharyngitisInfections and infestations | 14/25 |
| upper respiratory tract infectionInfections and infestations | 14/25 |
| influenzaInfections and infestations | 8/25 |
| pharyngitisInfections and infestations | 8/25 |
| gastroenteritisInfections and infestations | 6/25 |
| urticariaSkin and subcutaneous tissue disorders | 6/25 |
| iron deficiency anaemiaBlood and lymphatic system disorders | 5/25 |
| pyrexiaGeneral disorders | 5/25 |
| hordeolumInfections and infestations | 5/25 |
| eczemaSkin and subcutaneous tissue disorders | 5/25 |
| Age, Categorical(Participants) | Adalimumab |
|---|---|
| <=18 years | 25 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age Continuous(years) | Adalimumab |
|---|---|
| Mean | 13.0 ± 3.38 |
| Sex: Female, Male(Participants) | Adalimumab |
|---|---|
| Female | 20 |
| Male | 5 |
| Region of Enrollment(participants) | Adalimumab |
|---|---|
| Japan | 25 |
The record gives a start of May 2008, a primary completion of Mar 2010 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab